Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis. 2013

Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
Preclinical Neuroimmunology Laboratory, Neurology IV, Neurological Institute Carlo Besta, Milan, Italy.

Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12 mg/kg); this treatment allowed stable serum drug levels for at least 7 days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II
D060888 Real-Time Polymerase Chain Reaction Methods used for detecting the amplified DNA products from the polymerase chain reaction as they accumulate instead of at the end of the reaction. Kinetic Polymerase Chain Reaction,Quantitative Real-Time PCR,Quantitative Real-Time Polymerase Chain Reaction,Real-Time PCR,PCR, Quantitative Real-Time,PCR, Real-Time,PCRs, Quantitative Real-Time,PCRs, Real-Time,Quantitative Real Time PCR,Quantitative Real Time Polymerase Chain Reaction,Quantitative Real-Time PCRs,Real Time PCR,Real Time Polymerase Chain Reaction,Real-Time PCR, Quantitative,Real-Time PCRs,Real-Time PCRs, Quantitative
D020720 Myasthenia Gravis, Autoimmune, Experimental Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3) Myasthenia Gravis, Experimental Autoimmune,Passive Transfer Experimental Autoimmune Myasthenia Gravis,Autoimmune Experimental Myasthenia Gravis,Experimental Autoimmune Myasthenia Gravis, Passive Transfer,Experimental Myasthenia,Experimental Myasthenia Gravis,Myasthenia Gravis, Autoimmune Experimental,Experimental Myasthenias,Myasthenia Gravis, Experimental,Myasthenia, Experimental,Myasthenias, Experimental

Related Publications

Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
July 2016, Neuroscience letters,
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
February 2008, Journal of immunology (Baltimore, Md. : 1950),
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
October 1999, Annals of neurology,
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
March 2016, Clinical immunology (Orlando, Fla.),
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
July 1969, Lancet (London, England),
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
September 1969, Lancet (London, England),
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
January 1971, Research publications - Association for Research in Nervous and Mental Disease,
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
October 1985, Journal of neuroimmunology,
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
January 1976, Annals of the New York Academy of Sciences,
Roberta Marolda, and Chiara Ruocco, and Chiara Cordiglieri, and Chiara Toscani, and Carlo Antozzi, and Renato Mantegazza, and Fulvio Baggi
May 2000, Annales de medecine interne,
Copied contents to your clipboard!